"With the support from our syndicate of specialist life science investors, alongside the expertise of our Scientific Advisory Board, we are eager to advance our innovative therapeutic approach and improve patient outcomes," says Ben Nichols, CEO of Alveron Pharma.
The synthetic drug, OKL-1111, aims to prevent hematoma expansion and improve outcomes for patients with intracerebral hemorrhage, functioning within 10 minutes of diagnosis.
Current treatments for ICH patients taking anticoagulants are complicated and often take too long, sometimes over two hours, which can lead to worse results.
Broadview Ventures is a mission-driven investment organization that focuses on early-stage companies developing innovative therapeutics for cardiovascular disease and stroke.
Collection
[
|
...
]